Anticipated Q4 earnings per share (EPS) of -$0.03 with projected revenue of $43.8 million.
Negative price-to-earnings (P/E) ratio of -3.06, indicating ongoing challenges in achieving profitability.
Strong liquidity position with a current ratio of approximately 4.29, showcasing the company’s ability to cover its liabilities.
Organigram Holdings Inc. (NASDAQ: OGI, TSX: OGI) is a key player in the cannabis industry, known for producing high-quality cannabis products. The company is set to release its fourth quarter and fiscal 2024 earnings on December 18, 2024. This release will be followed by a conference call to discuss the results, providing insights into the company’s financial health.
Wall Street anticipates OGI’s earnings per share (EPS) to be -$0.03, with projected revenue of $43.8 million. Despite these expectations, OGI’s current financial metrics reveal challenges. The company has a negative price-to-earnings (P/E) ratio of -3.06, indicating ongoing negative earnings. This suggests that the company is not currently profitable.
OGI’s price-to-sales ratio is approximately 1.45, showing that investors are willing to pay $1.45 for every dollar of sales. This ratio is a measure of how much investors value the company’s sales. Additionally, the enterprise value to sales ratio is about 0.96, which may suggest a relatively low valuation compared to its sales.
The company’s enterprise value to operating cash flow ratio is around -7.61, reflecting negative operating cash flow. This indicates that OGI is not generating positive cash flow from its operations. Furthermore, the earnings yield is approximately -32.71%, reinforcing the negative earnings situation.
Despite these challenges, OGI maintains a strong liquidity position with a current ratio of approximately 4.29. This means the company has more than enough current assets to cover its current liabilities. Additionally, OGI has a very low debt-to-equity ratio of about 0.00034, indicating minimal reliance on debt financing.
